<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="/images/favicon.png" type="image/x-icon">
  <title>Neonatal Hyperbilirubinemia</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


    <h1>Neonatal Hyperbilirubinemia</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
      <a id='top'></a>
  <article>

        <!-- LEARNING OBJECTIVES CONTAINER  -->
            <div class="custom-card" id="custom-card-1">
              <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
              <div class="title"> 
                <h2>What You Will Learn</h2>
              </div>
              <div class="line">
                <p>After reading this note, you should be able to...</p>
              </div>
              <div class="content">
                <ul>
                  <li><i>This content is not available yet.</i></li>
              </ul>
              </div>
              <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
            </div>
          
        <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
      
      
        <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
          <div class="outline2">
      
            <input type="radio" name="control-2" id="show-2">
            <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
            <input type="radio" name="control-2" id="hide-2">
            <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
            <div class="contents">
              <div class="icon-box">
                <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                <img src="../images/icons/book.png" alt="Icon" class="icon">
              </div>
              <div id="tableOfContents">
                  <ol id="tocList"></ol>
              </div>
            </div>
           <div>
      
      <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->

      <br>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Overview</a>
          </h2>
        </header>
        <div class='body'>
          <p>This is an elevation in serum bilirubin</p>
          <p>Hyperbilirubinemia exists in 2 forms</p>
          <ul>
            <li>Unconjugated </li>
            <li>Conjugated     </li>
          </ul>
          <p>The management concerns are:</p>
          <ul>
            <li>Bilirubin encephalopathy -unconjugated </li>
            <li>Severity of underlying illness-conjugated</li>
          </ul>
          <p>Hyperbilirubinaemia is very common in the 1st week of life</p>
          <p>Occurring in 60% of term babies and 80% of preterm babies</p>

          <h4>Specific issues in Management</h4>
          <ul>
            <li>Level: What is the serum bilirubin level? </li>
            <li>Type: Is it conjugated or un-conjugated?</li>
            <li>Aetiology: What is the specific cause of the NNH?</li>
            <li>Physiological vs. Non Physiological</li>
            <li>For non-physiological: Increased production/ Decreased Secretion</li>
            <li>Severity: Encephalopathy imminent, present or unlikely?</li>
            <li>Treatment: What is the choice of treatment?</li>
            <li>Complications: What further anticipatory care is required?</li>
            <li>Prevention: What preventive measure is needed?</li>
          </ul>

          <h4>Definitions</h4>
          <ul>
            <li>NNH is an elevation of serum bilirubin > 17¬µmol/L or > 1mg/dl </li>
            <li>Jaundice is yellowish discoloration of skin and sclera secondary to accumulation of bilirubin in blood.</li>
            <li>Jaundice normally occurs when serum bilirubin is ‚â• 6mg/dl. (eye of the beholder)</li>
          </ul>
        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Bilirubin Metabolism</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Between 17-30 weeks the ability of the fetal liver to clear bilirubin is severely limited because UDP-Glucoronosyl transferase activity is only 0.1% of adult values</li>
              <li>This increases tenfold to 1% btw 30-40wks</li>
              <li>After birth it increases exponentially reaching adult levels in 6-14wks independent of GA</li>
              <li>The major route of fetal bilirubin excretion is across the placenta</li>
            </ul>

            <figure>
              <img src="../figures/nn-hyperbili (1).png" alt="">
              <figcaption>1g of Haemoglobin yields 35mg of bilirubin  </figcaption>
            </figure>

            <figure>
              <img src="../figures/nn-hyperbili (3).png" alt="">
              <figcaption>Biliverdin reductase </figcaption>
            </figure>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Classification </a>
          </h2>
        </header>
        <div class='body'>
          <ul>
            <li>Physiologic/Non-physiologic (pathologic)</li>
            <li>Conjugated/unconjugated</li>
            <ul>
              <li>	Once more than 20% of total bilirubin is conjugated, it is classified as conjugated. </li>
            </ul>
          </ul>

          <h4>Commonest Causes in UITH</h4>
          <ul>
            <li>Physiologic</li>
            <li>Non-physiologic</li>
            <ul>
              <li>ABO incompatibility</li>
              <li>G6PD deficiency</li>
              <li>Rh incompatibility</li>
              <li>Infections (sepsis, congenital, hepatitis)</li>
            </ul>
          </ul>

          <section id='heading-3-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-1'>Physiologic Jaundice</a>
              </h3>
            </header>
            <div class='body'>
               <p>Jaundice attributable to immaturity of the newborn organ and systems</p>
               <h4>CRITERIA FOR PHYSIOLOGIC JAUNDICE</h4>
               <ul>
                <li>Onset‚Äî Not before 24hours</li>
                <li>Daily rise‚Äî Does not exceed 5mg/dl</li>
                <li>Peak level‚Äî 12mg/dl in Term and 15mg/dl in Preterms</li>
                <li>Peak duration‚Äî 3rd ‚Äì 5th day in Term; 5th ‚Äì 7th in Preterms</li>
                <li>Duration‚Äî 7-10days in term babies and 2-3weeks in preterms</li>
                <li>Conjugated fraction‚Äî Does not exceed 10% of total</li>
               </ul>

               <h4>MECHANISM OF PHYSIOLOGIC JAUNDICE</h4>
               <ul>
                <li>Increased Bilirubin load on liver cell</li>
                <ul>
                  <li>Increase RBC volume, decrease RBC survival, increased E-H circulation</li>
                </ul>
                <li>Defective hepatic uptake of bilirubin</li>
                <ul>
                  <li>Decrease Ligandin (Y-protein)</li>
                </ul>
                <li>Defective bilirubin conjugation</li>
                <ul>
                  <li>Decrease activity of transferase enzyme (UDPGT ‚Äì Uridyldiglucoronosyl Transferase)</li>
                </ul>
                <li>Defective bilirubin excretion.</li>
                <ul>
                  <li>Excretion impaired but not rate-limiting</li>
                </ul>
               </ul>

               <h4>Major Reasons why a baby will have physiologic jaundice</h4>
               <ol>
                <li>Increased red cell mass</li>
                <li>Reduced red cell survival</li>
                <li>Reduction in activity of UDPGT</li>
               </ol>
               <p>In addition </p>
               <ul>
                <li>Infants lack the bacterial flora necessary to convert bilirubin to urobilinogen, so unconjugated bilirubin persists throughout the entire GI tract.</li>
                <li>Also, meconium contains large amounts of unconjugated bilirubin </li>
                <li>Intensity and duration of physiologic jaundice varies widely</li>
               </ul>
            </div>
          </section>

          <section id='heading-3-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-2'>Non-Physiologic Jaundice</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Jaundice due to other aggravating factors</li>
                <li>Failure to meet at LEAST ONE of the CRITERIA for Physiological HB</li>
                <li>Note however that in majority of cases etiology is unknown</li>
               </ul>

               <h4>CAUSES OF UNCONJUGATED NON-PHYSIOLOGICAL HYPERBILIRUBINAEMIA</h4>
               <ol>
                <li>Over Production of Bilirubin</li>
                <p>Haemolytic </p>
                <ul>
                  <li>Antibody mediated haemolysis </li>
                  <ul>
                    <li>ABO Incompatibility, Rh Incompatibility</li>
                    <li>Minor blood group incompatibility (anti-E & c, anti-Kell)</li>
                  </ul>
                  <li>Red Cell Enzyme defects</li>
                  <ul>
                    <li>G-6-P-D, Pyruvate kinase deficiency</li>
                  </ul>
                  <li>Red Cell Membrane defects</li>
                  <li>Hereditary spherocytosis, Elliptocytosis</li>
                </ul>

                <p>Extravascular Blood</p>
                <ul>
                  <li>Bruises, IVH,  Cephalohaematoma, Subgaleal hematoma</li>
                </ul>

                <p>Drug Induced Hemolysis</p>
                <ul>
                  <li>Vitamin K3 induced haemolysis</li>
                </ul>

                <p>Polycythaemia</h4>
                
                <li>Conjugation Defects</li>
                <p>Inherited reduction in glucoronosyl transferase </p>
                <ul>
                  <li>Familial non-haemolytic jaundice (Crigler-Najjar type I)</li>
                  <ul>
                    <li>Autosomal recessive, Severe</li>
                  </ul>
                  <li>Familial non-haemolytic jaundice (Crigler-Najjar type II)</li>
                  <ul>
                    <li>Autosomal dominant, milder cause</li>
                  </ul>
                </ul>
                <p>Abnormal glucoronyl transferase</p>
                <ul>
                  <li>Gilbert Syndrome</li>
                </ul>
                <p>Acquired inhibition of glucorosyl tranferase</p>
                <ul>
                  <li>Breast milk jaundice (5-b-pregnane-3a,20-b-diol or nonesterified long chain fatty acids) glucoronidase in some milk</li>
                </ul>
               </ol>

               <h4>CAUSES OF CONJUGATED NON-PHYSIOLOGICAL HYPERBILIRUBINAEMIA</h4>
               <ol>
                <li>Decreased Secretion</li>
                <p>Impaired transport of the hepatocytes</p>
                <ul>
                  <li>Congenital transport defect: Dubin-Johnson, Rotor syndrome</li>
                  <li>Hepatocellular damage secondary to metabolic disorders (galactosaemia)</li>
                </ul>
                <p>Obstruction of bile flow:</p>
                <ul>
                  <li>Biliary atresia, extrinsic obstruction (intestinal obstruction) choledochal cyst</li>
                </ul>
                <li>Mixed </li>
                <ul>
                  <li>Prenatal infections</li>
                  <li>Sepsis</li>
                  <li>Multi-system disorders</li>
                  <ul>
                    <li>IDM, Perinatal asphyxia</li>
                  </ul>
                </ul>
               </ol>
            </div>
          </section>
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Common Non-Physiological Causes</a>
          </h2>
        </header>
        <div class='body'>
          <section id='heading-4-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-1'>Iso-Immune Haemolytic Diseases</a>
              </h3>
            </header>
            <div class='body'>
               <h4>ABO Haemolytic Disease</h4>
               <p>Description </p>
               <ul>
                <li>Action of maternal anti-A or anti-B antibodies on fetal erythrocytes of the corresponding blood group</li>
                <li>It is the commonest cause of Non-physiologic hyperbilirubinaemia</li>
               </ul>
               <p>Pathogenesis</p>
               <ul>
                <li>Group O subjects have Anti-A or Anti-B antibodies of the IgG and IgM subclass in their plasma.</li>
                <li>In the event of a pregnancy with appropriate set up the IgG anti-A or anti-B antibodies cross the placenta to attack the fetal RBC</li>
                <li>These results in damage to erythrocytes and their destruction by the RES</li>
                <li>Attempts at repairing the partially damaged erythrocytes results in the formation of microspherocytes.</li>
               </ul>
               <p>Characteristics of ABO disease</p>
               <ul>
                <li>May affect first child</li>
                <li>Degree of severity is similar among siblings</li>
                <li>Early non-physiological jaundice</li>
                <li>Anaemia may be mild or non-existent</li>
               </ul>
               <p>Criteria for diagnosis</p>
               <ul>
                <li>Unconjugated hyperbilirubinaemia</li>
                <li>Jaundice during the first 24 hours</li>
                <li>An A or B baby of an O mother</li>
                <li>Increased number of microspherocytes</li>
                <li>Positive Coombs test </li>
                <li>Increased RBC production in the blood </li>
                <li>Reticulocytosis</li>
               </ul>


               <h4>Rhesus incompatibility</h4>
               <p>Description </p>
               <ul>
                <li>Due to action of maternal anti-D antibodies on the Rhesus antigen of fetal erythrocytes </li>
               </ul>
               <p>Pathogenesis</p>
               <ul>
                <li>It is due to the entry of fetal cells into the maternal circulation</li>
                <li>As few as 0.05-0.1ml of cells is enough to produce immunization</li>
                <li>Following sensitization, Rh-negative subjects produce anti-D antibodies of the IgG class</li>
                <li>The antibodies crosses the placenta to attack fetal RBC</li>
                <li>The anti-body coated RBC is removed by the spleen in the fetus</li>
                <li>Before birth the main danger is anaemia</li>
                <li>After birth it is severe hyperbilirubinaemia</li>
                <li>In utero there is increase rate of erythrocyte production-</li>
                <ul>
                  <li>Reticulocytosis and Nrbc</li>
                </ul>
                <li>Resulting in increased extramedullary erythropoiesis ‚Äì liver, spleen and lungs</li>
                <li>Most severe infants manifest hydrops fetalis</li>
                <li>Massive edema, ascites and pleural effusion. </li>
                <li>Can lead to baby being stillborn</li>
               </ul>
               <p>Characteristics of Rh disease</p>
               <ul>
                <li>Spares the first pregnancy</li>
                <li>Increasing degree of severity with subsequent pregnancies</li>
                <li>Early non-physiological jaundice</li>
                <li>Anaemia usually profound</li>
                <li>Hepatosplenomegally</li>
               </ul>
               <p>Criteria for diagnosis</p>
               <ul>
                <li>Unconjugated hyperbilirubinaemia</li>
                <li>Jaundice during the first 24 hours</li>
                <li>Rh-Positive baby  of Rh-negative mother</li>
                <li>Low Hb or PCV </li>
                <li>Strongly positive Coombs test </li>
                <ul>
                  <li>Reticulocytosis</li>
                  <li>Elevated levels of carboxyhaemoglobin</li>
                </ul>
               </ul>
               
               <p>Prevention</p>
               <ul>
                <li>Focuses primarily on the administration of anti-D immunoglobulin to mothers after delivery or abortion of an Rh-positive fetus.</li>
                <li>This is in the form of human anti-D concentrate called RhoGAM (300ug)</li>
                <li>Acid elution test of Kleihauer and Betke can be used to detect cases of massive transplacental haemorrhage that will require larger doses of anti-D immunoglobulin</li>
               </ul>
            </div>
          </section>

          <section id='heading-4-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-2'>G6PD Deficiency</a>
              </h3>
            </header>
            <div class='body'>
               <h4>Pathogenesis</h4>
               <ul>
                <li>RBC are liable to damage from oxidants</li>
                <li>Resulting in the formation of oxidized Hb which precipitates as Heinz  bodies</li>
                <li>G6PD necessary for protecting the RBC from this oxidative stress</li>
                <ul>
                  <li>Reduced GSH donates H- to reduce Oxidized Hb</li>
                  <li>The Oxidized GSSH is reduced by NADPH</li>
                  <li>The NADPH is derived from the HMP shunt at the G-6-PD step</li>
                </ul>
               </ul>
               <h4>Precipitants of acute haemolysis include</h4>
               <ul>
                <li>Drugs</li>
                <ul>
                  <li>Primaquine</li>
                  <li>Nitrofurantoin</li>
                  <li>Sulfonamides</li>
                  <li>Nalidixic Acid</li>
                  <li>Methylene blue</li>
                </ul>
                <li>Infections</li>
                <li>Naphthalene balls</li>
               </ul>
            </div>
          </section>

          <section id='heading-4-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-3'>Breast Milk Jaundice</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>There is significant and prolonged elevation of un-conjugated Br</li>
                <li>Incidence is very low</li>
                <li>Usually a diagnosis of exclusion</li>
                <li>Thought to be due to </li>
                <ul>
                  <li>The inhibition of the Glucoronosyl transferase by a steroid 3-a,20Œ≤ pregnanediol</li>
                  <li>Excess lipase librating FFA which interfere with protein binding and conjugation</li>
                </ul>
               </ul>

               <h4>Clinical course</h4>
               <ul>
                <li>Usually noticed from the 5th day </li>
                <li>Continues to increase to the second week</li>
                <li>Essentially un-conjugated</li>
                <li>Has now been  reported to be associated with Br Encephalopathy (previously, it was thought that it couldn‚Äôt result in encephalopathy)</li>
               </ul>
               
            </div>
          </section>
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Bilirubin Toxicity</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Kernicterus‚Äî pathologist‚Äôs term </li>
              <li>Bilirubin encephalopathy‚Äî general term</li>
              <li>Accumulates in the basal ganglia, hippocampus, cranial nerve nuclei, cerebellar nuclei and inferior olivary nuclei</li>
              <li>Original yellow deposits fade leaving dead neurons</li>
              <li>Results in permanent brain injury</li>
            </ul>

            <h4>Bilirubin Encephalopathy</h4>
            <p>Secondary to toxic effects of Br Acid on neurons </p>
            <p>Determinants of BE</p>
            <ul>
              <li>Concentration of Serum Unconjugated Br</li>
              <li>Concentration of serum albumin</li>
              <li>Bilirubin binding by albumin</li>
              <li>pH</li>
              <li>Integrity of the blood brain barrier</li>
              <li>Gestational Age</li>
            </ul>
            <p>Neuronal Injury</p>
            <ul>
              <li>BG, Brain stem nuclei for occulomotor function and brain stem auditory (cochlear) nuclei</li>
            </ul>
            <p>Staging</p>
            <ul>
              <li>Stage 1‚Äî Poor Moro, decreased tone, lethargy, poor suck, vomiting, High pitch cry</li>
              <li>Stage 2‚Äî Hypertonia, retrocollis, opisthotonus, oculo-gyric crises, paralysis of upward gaze. Many infants die at this stage</li>
              <li>Stage 3‚Äî Temporal evolution in tone: Hypernormal, Hypotonia, usually begins after the first week</li>
              <li>Stage 4‚Äî Chronic sequelae</li>
            </ul>

            <h4>Chronic Postkernicteric Encephalopathy</h4>
            <p>Includes cerebral palsy associated with:		</p>
            <ul>
              <li>Paralysis of upward gaze	</li>
              <li>High frequency hearing loss</li>
              <li>Athetosis					</li>
              <li>Mental retardation</li>
            </ul>
            <p>Evidence of neurological signs = permanent damage</p>

            <h4>BIND Score</h4>
            <p>This BIND assessment can also be used as part of the comprehensive assessment or used exclusively with infants with known hyperbilirubinemia to evaluate progression of symptoms of bilirubin toxicity.  </p>
            <figure>
              <img src="../figures/nn-hyperbili (1).jpg" alt="">
              <figcaption> </figcaption>
            </figure>
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Management </a>
          </h2>
        </header>
        <div class='body'>
          <section id='heading-6-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-1'>History</a>
              </h3>
            </header>
            <div class='body'>


              <!-- Trigger button -->
<button id="special-notes-trigger">Pediatric history outline</button>

<!-- Overlay -->
<div id="special-notes-overlay"></div>

<!-- Pop-up content -->
<div id="special-notes-popup">
  <h4>Pediatric history outline</h4>
  <p>Outline for documenting a pediatric medical history. It provides a structured framework for collecting comprehensive information about a child patient.</p>
  <ul>
    <li>Biodata</li>
    <li>Presenting complaint</li>
    <li>History of presenting complaint</li>
    <li>Past medical history</li>
    <li>Prenatal, natal and post-natal history</li>
    <li>Dietary/Nutritional history</li>
    <li>Immunization history</li>
    <li>Developmental history</li>
    <li>Family and social history</li>
    <li>Drug and allergy history</li>
    <li>Review of systems</li>
    <li>Summary</li>
  </ul>
  <button id="special-notes-close">Close</button>
</div>

              <h4>Introduction</h4>
              <ul>
                  <li><b>Introduce Yourself:</b> "Good day, I am Dr. [Your Name], and I will be taking care of your baby today. May I know your name and relationship to the baby?"</li>
                  <li><b>Confirm Patient‚Äôs Identity:</b> "Could you please tell me your baby‚Äôs name and date of birth?"</li>
                  <li><b>Explain Purpose:</b> "I‚Äôd like to ask some questions to understand why your baby has jaundice. Is that okay with you?"</li>
              </ul>
              
              <h4>Biodata</h4>
              <ul>
                  <li><b>Baby‚Äôs age:</b> (in days or weeks) and sex.</li>
                  <li><b>Place of delivery:</b> Home, health center, or hospital.</li>
                  <li><b>Gestational age:</b> Term, preterm, or post-term.</li>
                  <li><b>Birth weight</b> and <b>current weight.</b></li>
              </ul>
              
              <h4>History of Presenting Complaint</h4>
              <ol>
                  <li><b>Time of Detection:</b>
                      <ul>
                          <li>When was the yellow discoloration of the skin or eyes first noticed?</li>
                          <li>Was it within the <b>first 24 hours, day 2‚Äì7, or after 7 days?</b></li>
                          <li>Where was it first observed (e.g., face, chest, limbs)?</li>
                      </ul>
                  </li>
                  <li><b>Progression:</b>
                      <ul>
                          <li>Has the jaundice <b>spread or worsened?</b></li>
                          <li>Is it <b>resolving or staying the same?</b></li>
                      </ul>
                  </li>
                  <li><b>Associated Symptoms:</b>
                      <ul>
                          <li><b>Feeding:</b> Is the baby breastfeeding or formula-fed? Any difficulties with feeding (e.g., poor latching, low milk supply)?</li>
                          <li><b>Activity:</b> Is the baby lethargic, excessively sleepy, or irritable?</li>
                          <li><b>Crying:</b> Any high-pitched or excessive crying?</li>
                          <li><b>Urine:</b> Is the urine dark or yellow-stained? How frequently does the baby urinate?</li>
                          <li><b>Stool:</b> Is the stool pale, normal, or greenish? Frequency and consistency?</li>
                      </ul>
                  </li>
                  <li><b>Features Suggestive of Bilirubin Encephalopathy:</b>
                      <ul>
                          <li>Lethargy, poor feeding, high-pitched crying, arching of the back, or seizures.</li>
                      </ul>
                  </li>
                  <li><b>Interventions:</b>
                      <ul>
                          <li>Have any treatments been given (e.g., phototherapy, medications)?</li>
                          <li>Was the baby admitted to the hospital? For how long?</li>
                          <li>Any use of traditional remedies or substances?</li>
                      </ul>
                  </li>
                  <li><b>Exposure to Substances:</b>
                      <ul>
                          <li>Has the baby been exposed to hepatotoxic substances (e.g., camphor, menthol-containing substances)?</li>
                      </ul>
                  </li>
              </ol>
              

              <h4>Birth and Perinatal History</h4>
              <ol>
                  <li><b>Antenatal History:</b>
                      <ul>
                          <li>Were there any <b>complications during pregnancy</b> (e.g., infections, diabetes, hypertension)?</li>
                          <li>Any maternal illness, especially during the <b>first trimester</b> (e.g., TORCH infections)?</li>
                          <li>Medications or herbal remedies taken during pregnancy?</li>
                          <li><b>Mother‚Äôs blood group</b> and <b>Rh status?</b></li>
                      </ul>
                  </li>
                  <li><b>Birth History:</b>
                      <ul>
                          <li><b>Place of delivery:</b> Was the baby born at home, in a health center, or in a hospital?</li>
                          <li><b>Mode of delivery:</b> Vaginal delivery, cesarean section, or instrumental delivery (e.g., vacuum extraction, forceps)?</li>
                          <li><b>Gestational age:</b> Term, preterm, or post-term?</li>
                          <li><b>Birth weight:</b> Baby‚Äôs weight at birth?</li>
                          <li><b>Immediate condition:</b> Did the baby cry immediately after birth? Was there any need for resuscitation?</li>
                          <li><b>Delayed Cord Clamping:</b> Was it practiced?</li>
                      </ul>
                  </li>
                  <li><b>Neonatal Drugs:</b>
                      <ul>
                          <li>Was the baby given any medications (e.g., chloral hydrate, pancuronium, vitamin K3, novobiocin)?</li>
                      </ul>
                  </li>
                  <li><b>Hospital Stay:</b>
                      <ul>
                          <li>Was the hospital stay <b>short or prolonged?</b></li>
                          <li>Any concerns raised before discharge?</li>
                      </ul>
                  </li>
              </ol>
              
              <h4>Family History</h4>
              <ol>
                  <li><b>Jaundice in Siblings:</b>
                      <ul>
                          <li>Did any previous children have jaundice? How severe was it? How was it treated?</li>
                      </ul>
                  </li>
                  <li><b>Blood Group and Rh Compatibility:</b>
                      <ul>
                          <li>Is there a known history of blood group or Rh incompatibility in the family?</li>
                      </ul>
                  </li>
                  <li><b>Hereditary Conditions:</b>
                      <ul>
                          <li>Any family history of <b>hemolytic diseases</b>, G6PD deficiency, or other enzyme deficiencies?</li>
                          <li>History of liver or metabolic diseases?</li>
                      </ul>
                  </li>
              </ol>
              
              <h4>Nutritional History</h4>
              <ol>
                  <li><b>Breastfeeding:</b>
                      <ul>
                          <li>Is the baby breastfeeding exclusively, mixed feeding, or formula-fed?</li>
                          <li>Any difficulties with feeding, such as latching or inadequate milk supply?</li>
                      </ul>
                  </li>
                  <li><b>Formula Feeding:</b>
                      <ul>
                          <li>Type and preparation methods of formula used?</li>
                      </ul>
                  </li>
              </ol>

              <h4>Social History</h4>
              <ol>
                  <li><b>Maternal Health:</b>
                      <ul>
                          <li>How is the mother‚Äôs health and well-being post-delivery?</li>
                      </ul>
                  </li>
                  <li><b>Cultural Practices:</b>
                      <ul>
                          <li>Any use of herbal remedies or traditional practices for jaundice?</li>
                      </ul>
                  </li>
              </ol>
              
              <h4>Immunization History</h4>
              <ul>
                  <li>Has the baby received the <b>BCG</b> and <b>Hepatitis B</b> vaccines at birth?</li>
              </ul>
              
              <h4>Review of Systems</h4>
              <ol>
                  <li><b>Hematologic:</b>
                      <ul>
                          <li>Any signs of anemia (e.g., pallor) or bruising?</li>
                      </ul>
                  </li>
                  <li><b>Hepatic:</b>
                      <ul>
                          <li>Any concerns about liver swelling or masses?</li>
                      </ul>
                  </li>
                  <li><b>General Well-being:</b>
                      <ul>
                          <li>Any episodes of fever, irritability, or unusual behavior?</li>
                      </ul>
                  </li>
              </ol>
              
              <h4>Summarize and Close</h4>
              <ul>
                  <li><b>Summarize:</b> Recap key points from the history to confirm understanding.</li>
                  <li><b>Ask:</b> "Is there anything else you would like to add or ask about your baby?"</li>
                  <li><b>Thank:</b> "Thank you for sharing this information. It will help us understand your baby‚Äôs condition better."</li>
              </ul>
              

            </div>
          </section>

          <section id='heading-6-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-2'>Physical Examinations</a>
              </h3>
            </header>
            <div class='body'>
              <h4>Introduction</h4>
              <ul>
                  <li><b>Preparation:</b>
                      <ul>
                          <li>Wash hands thoroughly and ensure a clean, warm, and well-lit examination area.</li>
                          <li>Gather necessary equipment: <b>stethoscope</b>, <b>thermometer</b>, <b>measuring tape</b>, <b>gloves</b>, and a <b>flashlight</b> or <b>pen torch</b>.</li>
                      </ul>
                  </li>
                  <li><b>Introduction and Consent:</b>
                      <ul>
                          <li>Introduce yourself: "Good day, I am Dr. [Your Name], and I will be examining your baby today."</li>
                          <li>Explain the procedure: "This examination will involve assessing your baby's skin, eyes, abdomen, and general well-being to evaluate jaundice."</li>
                          <li>Obtain verbal consent.</li>
                      </ul>
                  </li>
              </ul>
              
              <h4>General Observation</h4>
              <ul>
                  <li><b>Appearance:</b>
                      <ul>
                          <li>Assess the baby‚Äôs overall condition, activity level, and posture.</li>
                          <li>Look for lethargy, irritability, or abnormal postures (e.g., opisthotonic posture indicating kernicterus).</li>
                      </ul>
                  </li>
                  <li><b>Color:</b>
                      <ul>
                          <li>Examine the skin, sclerae, and mucous membranes for yellow discoloration under natural light or with a flashlight.</li>
                          <li>Use <b>Kramer‚Äôs Rule</b> to estimate bilirubin levels:
                              <ul>
                                  <li><b>Face:</b> 5-6 mg/dL</li>
                                  <li><b>Chest/Nipple Line:</b> 8 mg/dL</li>
                                  <li><b>Abdomen:</b> 10 mg/dL</li>
                                  <li><b>Knees:</b> 15 mg/dL</li>
                                  <li><b>Feet:</b> 20 mg/dL</li>
                              </ul>
                          </li>
                      </ul>
                  </li>
                  <li><b>Hydration:</b>
                      <ul>
                          <li>Assess mucous membranes, fontanelle (sunken in dehydration), skin turgor, and capillary refill time.</li>
                      </ul>
                  </li>
                  <li><b>Vital Signs:</b>
                      <ul>
                          <li>Measure temperature (hypothermia or fever may indicate sepsis).</li>
                          <li>Assess heart and respiratory rates.</li>
                      </ul>
                  </li>
              </ul>
              

              <h4>Systematic Examination</h4>

              <h5>Head and Neck</h5>
              <ul>
                  <li><b>Fontanelles:</b>
                      <ul>
                          <li>Palpate for bulging (raised intracranial pressure) or sunken fontanelles (dehydration).</li>
                      </ul>
                  </li>
                  <li><b>Eyes:</b>
                      <ul>
                          <li>Inspect sclerae for icterus.</li>
                          <li>Note any sunset sign or abnormal eye movements.</li>
                      </ul>
                  </li>
                  <li><b>Oral Cavity:</b>
                      <ul>
                          <li>Check mucous membranes for jaundice.</li>
                          <li>Look for hydration status and tongue moistness.</li>
                      </ul>
                  </li>
                  <li><b>Cephalohematoma or Bruising:</b>
                      <ul>
                          <li>Palpate for birth trauma, as bruising increases bilirubin production.</li>
                      </ul>
                  </li>
              </ul>
              
              <h5>Chest and Cardiovascular System</h5>
              <ul>
                  <li><b>Inspection:</b>
                      <ul>
                          <li>Observe for pallor, cyanosis, and respiratory distress (e.g., nasal flaring, grunting, or retractions).</li>
                      </ul>
                  </li>
                  <li><b>Auscultation:</b>
                      <ul>
                          <li>Listen for murmurs (e.g., congenital heart defects).</li>
                          <li>Assess breath sounds bilaterally.</li>
                      </ul>
                  </li>
              </ul>
              
              <h5>Abdomen</h5>
              <ul>
                  <li><b>Inspection:</b>
                      <ul>
                          <li>Note abdominal distension, visible veins, or abnormalities of the umbilical stump.</li>
                      </ul>
                  </li>
                  <li><b>Palpation:</b>
                      <ul>
                          <li><b>Liver:</b> Check for hepatomegaly.</li>
                          <li><b>Spleen:</b> Assess for splenomegaly.</li>
                          <li><b>Masses:</b> Palpate for any unusual lumps.</li>
                      </ul>
                  </li>
                  <li><b>Umbilical Cord:</b>
                      <ul>
                          <li>Look for infection, delayed separation, or bleeding.</li>
                      </ul>
                  </li>
              </ul>
              
              <h5>Skin</h5>
              <ul>
                  <li><b>Extent of Jaundice:</b>
                      <ul>
                          <li>Perform blanching by applying light pressure to reveal the underlying skin color.</li>
                          <li>Confirm severity with Kramer‚Äôs zones or use instruments like an icterometer/bilirubinometer.</li>
                      </ul>
                  </li>
                  <li><b>Signs of Bleeding or Hemolysis:</b>
                      <ul>
                          <li>Look for petechiae, bruising, or pallor.</li>
                      </ul>
                  </li>
                  <li><b>Rashes:</b>
                      <ul>
                          <li>Check for erythema toxicum or septic skin lesions.</li>
                      </ul>
                  </li>
              </ul>
              
              <h5>Limbs and Extremities</h5>
              <ul>
                  <li><b>Tone and Reflexes:</b>
                      <ul>
                          <li>Assess muscle tone (e.g., hypo- or hypertonia).</li>
                          <li>Elicit primitive reflexes (e.g., Moro, rooting, sucking).</li>
                      </ul>
                  </li>
                  <li><b>Peripheral Jaundice:</b>
                      <ul>
                          <li>Examine palms and soles for jaundice (may indicate severe hyperbilirubinemia).</li>
                      </ul>
                  </li>
              </ul>
              
              <h5>Neurological Examination</h5>
              <ul>
                  <li><b>Alertness:</b>
                      <ul>
                          <li>Observe for lethargy or hyperalertness.</li>
                      </ul>
                  </li>
                  <li><b>Tone:</b>
                      <ul>
                          <li>Note hypo- or hypertonia, opisthotonic postures, or diminished Moro reflex.</li>
                      </ul>
                  </li>
                  <li><b>Crying:</b>
                      <ul>
                          <li>Assess for a high-pitched cry, which can suggest bilirubin encephalopathy.</li>
                      </ul>
                  </li>
                  <li><b>Seizures:</b>
                      <ul>
                          <li>Look for abnormal movements or jerking.</li>
                      </ul>
                  </li>
              </ul>
              
              <h5>Summary</h5>
              <ul>
                  <li><b>Document Findings:</b>
                      <ul>
                          <li>Record signs of jaundice, dehydration, or neurological abnormalities.</li>
                          <li>Note associated findings such as hepatosplenomegaly or cephalohematoma.</li>
                      </ul>
                  </li>
                  <li><b>Plan:</b>
                      <ul>
                          <li>Correlate findings with history and initiate further investigations:
                              <ul>
                                  <li>Total and direct bilirubin levels.</li>
                                  <li>Blood group typing and Coombs test.</li>
                                  <li>Complete blood count (CBC).</li>
                              </ul>
                          </li>
                      </ul>
                  </li>
                  <li><b>Communicate:</b>
                      <ul>
                          <li>Explain findings and management plan to the caregiver.</li>
                          <li>Offer reassurance and outline next steps.</li>
                      </ul>
                  </li>
                  <li><b>Thank the Caregiver:</b>
                      <ul>
                          <li>Conclude: "Thank you for your cooperation. We will take the necessary steps to ensure your baby receives the best care."</li>
                      </ul>
                  </li>
              </ul>
              
            </div>
          </section>

          <section id='heading-6-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-3'>Investigations</a>
              </h3>
            </header>
            <div class='body'>
              <h4>Investigations for Neonatal Jaundice/Hyperbilirubinemia</h4>

              <ol>
                <li>
                  <strong>Serum Bilirubin Levels</strong>
                  <ul>
                    <li><strong>Total Serum Bilirubin (TSB):</strong> Determines the severity of jaundice.</li>
                    <li><strong>Direct (Conjugated) and Indirect (Unconjugated) Bilirubin:</strong> Differentiates between conjugated and unconjugated hyperbilirubinemia.</li>
                    <li><strong>Transcutaneous Bilirubinometry (TcB):</strong> Non-invasive screening tool; requires confirmation with TSB if levels are elevated.</li>
                  </ul>
                </li>
              
                <li>
                  <strong>Blood Group and Rh Typing</strong>
                  <ul>
                    <li><strong>Maternal and Neonatal ABO and Rh Typing:</strong> Detects ABO or Rh incompatibility.</li>
                  </ul>
                </li>
              
                <li>
                  <strong>Hematological Tests</strong>
                  <ul>
                    <li>
                      <strong>Full Blood Count (FBC):</strong>
                      <ul>
                        <li>Assesses hemoglobin levels for anemia or polycythemia.</li>
                        <li>White blood cell and platelet counts can indicate infection or sepsis.</li>
                      </ul>
                    </li>
                    <li>
                      <strong>Peripheral Blood Smear:</strong>
                      Detects abnormal red cell morphology, such as spherocytes (<em>hereditary spherocytosis</em>) or fragmented cells (<em>hemolysis</em>).
                    </li>
                    <li><strong>Reticulocyte Count:</strong> Elevated levels indicate active hemolysis.</li>
                    <li><strong>Direct Antiglobulin Test (DAT/Coombs Test):</strong> Confirms immune-mediated hemolysis.</li>
                    <li><strong>G6PD Activity:</strong> Screens for G6PD deficiency, a common cause of hemolysis in susceptible populations.</li>
                  </ul>
                </li>
              
                <li>
                  <strong>Infection Screening</strong>
                  <ul>
                    <li><strong>Blood Culture:</strong> Detects bacteremia or sepsis.</li>
                    <li><strong>C-Reactive Protein (CRP) and Procalcitonin Levels:</strong> Elevated in sepsis or significant infection.</li>
                    <li><strong>Urine Culture:</strong> Screens for urinary tract infections, especially in prolonged jaundice.</li>
                  </ul>
                </li>
              
                <li>
                  <strong>Liver Function Tests (LFTs)</strong>
                  <ul>
                    <li><strong>ALT, AST, and GGT:</strong> Evaluate liver function and potential hepatocellular injury.</li>
                    <li><strong>Albumin and Total Protein:</strong> Assess liver synthetic function.</li>
                  </ul>
                </li>
              
                <li>
                  <strong>Thyroid and Metabolic Screening</strong>
                  <ul>
                    <li><strong>Thyroid Function Tests (TFTs):</strong> Rule out congenital hypothyroidism.</li>
                    <li><strong>Galactosemia Testing:</strong> Identify metabolic disorders that may present with jaundice.</li>
                  </ul>
                </li>
              
                <li>
                  <strong>Imaging Studies (if indicated)</strong>
                  <ul>
                    <li><strong>Abdominal Ultrasound:</strong> Examines liver, gallbladder, and biliary tree for structural anomalies like biliary atresia.</li>
                    <li><strong>Hepatobiliary Scintigraphy (HIDA Scan):</strong> Evaluates bile flow to confirm biliary obstruction or atresia.</li>
                    <li><strong>Chest X-ray:</strong> Rules out associated congenital anomalies.</li>
                  </ul>
                </li>
              
                <li>
                  <strong>Genetic and Specialized Tests</strong>
                  <ul>
                    <li><strong>Genetic Testing:</strong> Investigates hereditary conditions like Gilbert syndrome or Crigler-Najjar syndrome.</li>
                    <li><strong>Pyruvate Kinase Activity:</strong> Rules out rare enzymatic causes of hemolysis.</li>
                  </ul>
                </li>
              
                <li>
                  <strong>Stool and Urine Analysis</strong>
                  <ul>
                    <li><strong>Urinalysis:</strong> Detects bile pigments or reducing substances (e.g., in galactosemia).</li>
                    <li><strong>Stool Color:</strong> Pale stools suggest conjugated hyperbilirubinemia, indicating biliary obstruction.</li>
                  </ul>
                </li>
              </ol>
              
            </div>
          </section>

          <section id='heading-6-4'>
            <header>
              <h3>
                <a aria-hidden href='#heading-6-4'>Treatment</a>
              </h3>
            </header>
            <div class='body'>
               <ul>
                <li>Anticipatory care</li>
                <li>Phototherapy</li>
                <li>EBT</li>
               </ul>


               <figure>
                <img src="../figures/nn-hyperbili (2).png" alt="">
                <figcaption> Dermal Zones of Jaundice</figcaption>
              </figure>



              <h4>The Goal of Therapy</h4>
              <p>The goal of therapy is to <strong>prevent severe hyperbilirubinemia</strong> and its complications, such as <strong>kernicterus</strong> and <strong>bilirubin encephalopathy</strong>, without causing undue harm. Management strategies are tailored to the severity of jaundice and the underlying cause.</p>
              
              <hr>
              
              <section id='heading-6-4-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-6-4-1'>Phototherapy in Neonatal Jaundice</a>
                  </h3>
                </header>
                <div class='body'>

                  <p><strong>Phototherapy</strong> is a widely used, safe, and non-invasive treatment for neonatal jaundice, first described by Cremer et al. in 1958. It involves the use of light energy to convert unconjugated bilirubin into photo-bilirubin (also called lumirubin), which is more polar, less lipophilic, and easier to excrete via bile and urine. This helps reduce hyperbilirubinemia in newborns, particularly in those with neonatal jaundice.</p>
                  
                  <h4>Mechanism of Action</h4>
                  <ul>
                    <li><strong>Photo-isomerization of Bilirubin:</strong> Bilirubin absorbs light maximally in the blue spectrum (420-470 nm), leading to the photo-isomerization of unconjugated bilirubin into a more excretable form known as lumirubin. This lumirubin is more water-soluble and can be eliminated more easily through the urine and feces. The photo-isomerization process also helps reduce the serum concentration of unconjugated bilirubin.</li>
                  </ul>
                  
                  <h4>Indications for Phototherapy</h4>
                  <ul>
                    <li><strong>Prophylaxis in Preterm Low Birth Weight (LBW) Infants:</strong> Preventive treatment in preterm infants or those at risk of severe hyperbilirubinemia to avoid complications.</li>
                    <li><strong>Moderate Hyperbilirubinemia:</strong> Treatment for newborns with moderate levels of unconjugated hyperbilirubinemia (bilirubin levels above safe thresholds but not high enough to require exchange transfusion).</li>
                    <li><strong>Post-Exchange Blood Transfusion (EBT):</strong> After exchange transfusion, phototherapy is often used to accelerate the excretion of remaining bilirubin and prevent rebound hyperbilirubinemia.</li>
                  </ul>
                  
                  <h4>Contraindications</h4>
                  <ul>
                    <li><strong>Porphyria:</strong> Both personal and family history of porphyria are contraindications for phototherapy, as it may exacerbate the condition.</li>
                  </ul>
                  
                  <h4>Types of Phototherapy Lights</h4>
                  <ul>
                    <li><strong>Broad-spectrum White Light:</strong> A white light source with a broad spectrum, used for general phototherapy.</li>
                    <li><strong>Broad-spectrum Blue Light:</strong> Typically used because it is more efficient in the 420-470 nm range for bilirubin absorption.</li>
                    <li><strong>Narrow-spectrum Blue Light:</strong> More effective than broad-spectrum blue light due to its narrow wavelength range, minimizing unnecessary exposure to other parts of the spectrum.</li>
                    <li><strong>Fiber Optic Light:</strong> Used for fiber-optic phototherapy, which involves light delivered through fibers, often in the form of a blanket, reducing the need for direct light sources.</li>
                    <li><strong>Light Emitting Diode (LED):</strong> Modern, energy-efficient, and stable sources of light, offering targeted wavelength emissions for effective phototherapy.</li>
                  </ul>
                  
                  <h4>Principles of Phototherapy</h4>
                  <ul>
                    <li><strong>Bilirubin Absorption:</strong> Bilirubin absorbs light maximally in the blue range (420-470 nm), so effective phototherapy sources should emit light in this range.</li>
                    <li><strong>Influencing Factors for Phototherapy Efficacy:</strong>
                      <ul>
                        <li><strong>Irradiance:</strong> The intensity of light measured in mW/cm¬≤/nm. Higher irradiance leads to more effective treatment.
                          <ul>
                            <li><strong>Standard phototherapy:</strong> Typically provided at 8-10 mW/cm¬≤/nm.</li>
                            <li><strong>Intensive phototherapy:</strong> Delivered at 30-40 mW/cm¬≤/nm, used for more severe cases.</li>
                          </ul>
                        </li>
                        <li><strong>Distance from Light Source:</strong> The closer the light source is to the infant's skin, the more effective the therapy. The distance should generally be no greater than 50 cm. The distance can be reduced to 10-20 cm when temperature control is monitored carefully.</li>
                        <li><strong>Skin Exposure:</strong> The more skin exposed to the light, the more efficient the treatment. Removing clothing and placing the baby under the light while ensuring thermal regulation (temperature is controlled) is important.</li>
                      </ul>
                    </li>
                    <li><strong>Expected Efficacy:</strong> When delivered adequately, phototherapy should decrease bilirubin levels by approximately 1-2 mg/dL every 4-6 hours. The bilirubin reduction depends on factors like irradiance, skin exposure, and the newborn‚Äôs gestational age.</li>
                    <li><strong>Effectiveness in Dark Skin:</strong> Dark skin tones do not significantly reduce the efficacy of phototherapy. The light still penetrates and is absorbed by the bilirubin in the blood.</li>
                  </ul>
                  
                  <h4>Complications of Phototherapy</h4>
                  <ul>
                    <li><strong>Dehydration</strong>: Increased insensible water loss due to prolonged exposure to light. Infants undergoing phototherapy may require additional fluid intake to compensate for this.</li>
                    <li><strong>Greenish Stool</strong>: The stool may become loose and greenish due to the rapid excretion of photo-bilirubin.</li>
                    <li><strong>Erythematous Macular Rash</strong>: A temporary rash may develop, usually resolving after discontinuation of treatment.</li>
                    <li><strong>Retinal Damage</strong>: There is potential for retinal damage (documented in animal studies), particularly if the eyes are not adequately protected.</li>
                    <li><strong>Gonadal Damage</strong>: Prolonged exposure to phototherapy may alter gonadotropin levels, which could affect gonadal development. Gonads should be shielded to minimize risk.</li>
                    <li><strong>Patent Ductus Arteriosus (PDA)</strong>: Preterm infants undergoing phototherapy may experience PDA due to photo-relaxation of myocardial fibers, which can impact ductal closure.</li>
                    <li><strong>Bronze-Baby Syndrome</strong>: A rare condition where the skin develops a greyish-brown discoloration, which resolves after discontinuation of phototherapy.</li>
                    <li><strong>Other Potential Risks</strong>: Hemolysis (due to increased breakdown of RBCs), lactose intolerance, and hypocalcemia (due to changes in calcium metabolism) are rare but documented complications.</li>
                  </ul>
                  
                  <h4>Care for Infants Undergoing Phototherapy</h4>
                  <ul>
                    <li><strong>Fluid Management</strong>: Additional fluid intake of 20-30 mL/kg/day is necessary to compensate for insensible water loss.</li>
                    <li><strong>Eye Protection</strong>: The infant‚Äôs eyes should be protected from the direct light with eye shields, goggles, or lubricating eye drops to avoid retinal damage.</li>
                    <li><strong>Temperature Monitoring</strong>: The infant‚Äôs temperature should be closely monitored to prevent hyperthermia or hypothermia.</li>
                    <li><strong>Gonadal Protection</strong>: The gonads should be shielded from the light to reduce the risk of gonadal damage.</li>
                    <li><strong>Bilirubin Monitoring</strong>: Serum bilirubin levels should be measured every 12-24 hours to assess the effectiveness of phototherapy. If levels continue to rise, further interventions may be necessary.</li>
                  </ul>
                  
                  <h4>Note</h4>
                  <ul>
                    <li><strong>Duration of Phototherapy</strong>: The duration typically ranges from 48-72 hours, depending on the severity of jaundice and the infant‚Äôs response. If bilirubin levels continue to rise despite phototherapy, exchange transfusion may be required.</li>
                    <li><
                  
                </div>
              </section>

              <section id='heading-6-4-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-6-4-2'>Exchange Blood Transfusion (EBT)</a>
                  </h3>
                </header>
                <div class='body'>

                  <p>Exchange blood transfusion (EBT) involves the removal of the infant's blood in aliquots and replacing it with donor blood. This procedure rapidly lowers the infant's serum bilirubin concentration, removes sensitized red blood cells and circulating antibodies, and helps correct anemia. EBT is particularly effective in cases of severe hyperbilirubinemia that do not respond to phototherapy.</p>
                  
                  <h4>Mechanism of Action</h4>
                  <ul>
                    <li><strong>Removal of Bilirubin</strong>: The procedure helps lower bilirubin levels by removing a significant amount of the infant's blood (which contains high levels of unconjugated bilirubin) and replacing it with donor blood, which is free of bilirubin.</li>
                    <li><strong>Removal of Sensitized Red Blood Cells</strong>: It also removes sensitized red blood cells (from conditions like hemolytic disease of the newborn) and the circulating maternal antibodies, which can contribute to hemolysis.</li>
                    <li><strong>Correction of Anemia</strong>: EBT helps in correcting the anemia that can result from hemolysis or ineffective erythropoiesis.</li>
                  </ul>
                  
                  <h4>Key Technical Details of EBT</h4>
                  
                  <h4>Blood Preparation</h4>
                  <ul>
                    <li><strong>Crossmatching</strong>: Blood for the transfusion must be cross-matched against both the infant's and mother's serum to prevent transfusion reactions.</li>
                    <li><strong>Volume Exchange</strong>: The volume of blood exchanged is typically 5-20 ml at a time. The total volume exchanged can be single volume or double volume (the latter being more common).</li>
                    <ul>
                      <li><strong>Single volume exchange</strong>: Involves the replacement of a volume equivalent to the infant‚Äôs blood volume.</li>
                      <li><strong>Double volume exchange</strong>: Involves replacing twice the blood volume, which is often done in more severe cases.</li>
                    </ul>
                  </ul>
                  
                  <h4>Duration of Procedure</h4>
                  <p>The procedure generally takes 60-90 minutes. It is performed under strict monitoring to avoid complications.</p>
                  
                  <h4>Blood Volume</h4>
                  <ul>
                    <li><strong>Total blood volume of an infant</strong>:
                      <ul>
                        <li><strong>100 ml/kg</strong> in preterm infants</li>
                        <li><strong>80 ml/kg</strong> in term infants</li>
                      </ul>
                    </li>
                  </ul>
                  

                  <h4>Indications for EBT</h4>
                  <p>EBT is indicated in cases of severe hyperbilirubinemia where phototherapy has failed or where bilirubin levels pose an immediate risk of severe complications.</p>
                  <ul>
                    <li><strong>Serum Bilirubin Concentration</strong>:
                      <ul>
                        <li>‚â•10 mg/dL (170 ¬µmol/L) by 24 hours of age</li>
                        <li>>15 mg/dL (255 ¬µmol/L) by 48 hours of age</li>
                        <li>>20 mg/dL (340 ¬µmol/L) at any age</li>
                      </ul>
                    </li>
                    <li><strong>Rate of Rise</strong>: Bilirubin levels rising more than 5 mg/dL/day or >0.5 mg/dL/hr</li>
                  </ul>
                  
                  <h4>Methods of Exchange Blood Transfusion</h4>
                  
                  <h4>1. Push-Pull Method (More Common)</h4>
                  <ul>
                    <li><strong>Procedure</strong>: This method is commonly used in many settings, especially in resource-limited environments. A single umbilical vein catheter is inserted, and a 4-way stopcock is used to alternately remove 5-20 ml of the infant's blood and replace it with an equal or double volume of donor blood.</li>
                    <li><strong>Steps</strong>:
                      <ol>
                        <li>Remove a small aliquot of the infant's blood (5-20 ml).</li>
                        <li>Infuse the donor blood (double or single volume) into the infant‚Äôs bloodstream.</li>
                      </ol>
                    </li>
                  </ul>
                  
                  <h4>2. Isovolumetric Method</h4>
                  <ul>
                    <li><strong>Procedure</strong>: This method involves the slow removal of infant blood (5-10 ml) from an artery and simultaneous infusion of packed red blood cells through a vein.</li>
                    <li><strong>Advantages</strong>: It is associated with fewer complications than the push-pull method, especially when done under controlled conditions. It is less invasive as it does not require a stopcock mechanism.</li>
                  </ul>
                  
                  <h4>Complications of EBT</h4>

                  <h4>1. Catheter-Related Complications</h4>
                  <ul>
                    <li><strong>Infection</strong>: Septicemia due to catheter-related infections.</li>
                    <li><strong>Gut Perforation</strong>: The catheter may accidentally puncture the gut or other organs.</li>
                    <li><strong>Peritonitis</strong>: Infection in the peritoneal cavity, a potential result of gut perforation.</li>
                    <li><strong>Cardiac Arrhythmias</strong>: Due to rapid changes in blood volume and electrolyte imbalances.</li>
                    <li><strong>Necrotizing Enterocolitis (NEC)</strong>: A potentially life-threatening gastrointestinal condition, especially in preterm infants.</li>
                    <li><strong>Air Embolism</strong>: Occurs if air enters the catheter or blood supply during the procedure, which can be fatal.</li>
                  </ul>
                  
                  <h4>2. Transfusion-Related Complications</h4>
                  <ul>
                    <li><strong>Infection</strong>: Risk of transfusion-transmitted infections, such as malaria, hepatitis B (HBV), and HIV.</li>
                    <li><strong>Hypo or Hypervolemia</strong>: Both overtransfusion and undertransfusion can result in complications such as heart failure or poor perfusion.</li>
                    <li><strong>Transfusion Reactions</strong>: Immune responses can cause hemolysis, fever, or allergic reactions.</li>
                  </ul>
                  
                  <h4>3. Electrolyte and Metabolic Disturbances</h4>
                  <ul>
                    <li><strong>Hyperkalemia</strong>: A potentially dangerous rise in potassium levels due to the breakdown of red blood cells during the transfusion process.</li>
                    <li><strong>Hypocalcemia</strong>: Caused by the chelation of calcium by the citrate content in blood preservatives, which can lead to seizures or cardiac issues.</li>
                    <li><strong>Hypomagnesemia</strong>: Low magnesium levels may occur as a result of changes in blood composition.</li>
                    <li><strong>Acidosis</strong>: A buildup of acid in the blood due to metabolic disturbances during the procedure.</li>
                  </ul>
                  
                  <h4>4. Temperature and Glucose Imbalance</h4>
                  <ul>
                    <li><strong>Hypo or Hyperthermia</strong>: Temperature changes can occur during the procedure, particularly in preterm infants. Careful thermal regulation is important.</li>
                    <li><strong>Hyperglycemia</strong>: The glucose content in blood preservatives like Acid Citrate Dextrose (ACD) and Citrate Phosphate Dextrose (CPD) can cause elevated blood glucose levels.</li>
                    <li><strong>Hypoglycemia</strong>: A rebound effect due to insulin secretion triggered by hyperglycemia during the procedure.</li>
                  </ul>
                  
                  <h4>5. Thrombocytopenia</h4>
                  <ul>
                    <li>A reduction in platelet count that may occur due to the dilution effect of the transfused blood.</li>
                  </ul>
                  
                  <h4>Note</h4>
                  <ul>
                    <li><strong>Monitoring During Procedure</strong>: Continuous monitoring of vital signs, including heart rate, blood pressure, oxygen saturation, and temperature, is essential throughout the exchange.</li>
                    <li><strong>Post-EBT Monitoring</strong>: After the procedure, the infant‚Äôs bilirubin levels should be monitored closely to assess the effectiveness of the exchange and detect any rebound hyperbilirubinemia. Electrolyte levels should also be closely monitored to avoid complications.</li>
                  </ul>
                  
                </div>
              </section>
              

              <section id='heading-6-4-3'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-6-4-3'>Other Management Principles</a>
                  </h3>
                </header>
                <div class='body'>
                  <h4>Pharmacotherapy</h4>
                  <ul>
                    <li><strong>Intravenous Immunoglobulin (IVIG)</strong>: 
                      <ul>
                        <li>Indicated in immune-mediated hemolysis (e.g., Rh/ABO incompatibility).</li>
                        <li><strong>Dose</strong>: 500 mg/kg over 4‚Äì6 hours.</li>
                      </ul>
                    </li>
                    <li><strong>Phenobarbital</strong>: 
                      <ul>
                        <li>Enhances bilirubin conjugation by upregulating hepatic enzymes.</li>
                        <li>May be used antenatally (to mothers) or postnatally (to neonates).</li>
                      </ul>
                    </li>
                    <li><strong>Tin-Mesoporphyrin</strong>: 
                      <ul>
                        <li>Inhibits heme oxygenase, reducing bilirubin production.</li>
                      </ul>
                    </li>
                  </ul>
                  
                  <h4>Treatment of Underlying Causes</h4>
                  <ul>
                    <li><strong>Hemolysis</strong>: Manage conditions like G6PD deficiency or hereditary spherocytosis.</li>
                    <li><strong>Infection</strong>: Administer antibiotics for sepsis after cultures.</li>
                    <li><strong>Metabolic Disorders</strong>: Modify diet for conditions like galactosemia.</li>



                    <h4>Management of Conjugated Hb</h4>
                    <ul>
                      <li>Surgical hyperbilirubinemia</li>
                      <li>Investigations; LFT, ABD USS</li>
                      <li>Specific treatment depends on the cause</li>
                      <ul>
                        <li>Kasai procedure for biliary atresia</li>
                      </ul>
                    </ul>
                  </ul>
                  
                  <h4>Discharge and Follow-Up</h4>
                  <ul>
                    <li><strong>Criteria for Discharge</strong>: 
                      <ul>
                        <li>Serum bilirubin below phototherapy threshold.</li>
                        <li>Stable clinical condition and good feeding/weight gain.</li>
                      </ul>
                    </li>
                    <li><strong>Post-Discharge Monitoring</strong>: 
                      <ul>
                        <li>High-risk infants require repeat bilirubin levels within 1‚Äì2 days.</li>
                      </ul>
                    </li>
                    <li><strong>Parental Education</strong>: 
                      <ul>
                        <li>Inform caregivers to watch for signs of worsening jaundice (e.g., lethargy, poor feeding, pale stools).</li>
                      </ul>
                    </li>
                  </ul>
                  
                  <h4>Prevention</h4>
                  <ul>
                    <li><strong>Antenatal Care</strong>: 
                      <ul>
                        <li>Screen for Rh incompatibility and administer anti-D immunoglobulin as needed.</li>
                      </ul>
                    </li>
                    <li><strong>Postnatal Screening</strong>: 
                      <ul>
                        <li>Monitor high-risk neonates (e.g., preterm or with hemolysis).</li>
                      </ul>
                    </li>
                  </ul>
                  
    
                </div>
              </section>


            </div>
          </section>
        </div>
      </section>



      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://docs.google.com/forms/d/e/1FAIpQLSdx2teDCmW6ivSeKLQg7zF_jy7Yfg_1Gqm84_UT0PQPATsNug/viewform?usp=sf_link" class="comment-button">
            here
            <!-- <img src="../images/icons/whatsapp.png" alt="Image Icon"> -->
          </a>
        </div>


      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
 
